Abstract
Cancer is single most important risk factor for developing thromboembolism (VTE). Cancer patients are at increased risk of bleeding due to various reasons [1]. Low molecular weight heparin (LMWH) remained the standard of care for many years [2]. Direct acting oral anticoagulants (DOACs) are simpler to administer and equally effective and safe as compared to LMWH [2]. However, there are several concerns associated with DOACs in cancer patients. They are related to drug-to-drug interactions and risk of bleeding in gastrointestinal and urothelial malignancies [3]. Authors have comprehensively summarized the available evidence related to managing venous thromboembolism in cancer patients.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
